viewAusCann Group Holdings Ltd
The halt will remain in place until Friday 8th December 2017.
() is the only listed company that is integrated across the full spectrum of the Australian medicinal cannabis supply chain.
To provide details of the next steps in its Australian operations, the ASX has granted the company a trading halt to finalise.
READ: AusCann Group Holdings secures medical cannabis cultivation licence
The halt will remain in place until the opening of trade on Friday 8th December 2017, or earlier if an announcement is made to the market.
ASX:AC8
Market: ASX
Market Cap: $93.53 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of AusCann Group Holdings Ltd named herein, including the promotion by the Company of AusCann Group Holdings Ltd in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
Auscann targeting pain management with Australian cannabinoid products
Elaine Darby, managing director of Auscann Group Holdings Ltd (ASX:AC8), spoke to Proactive Investors at the ASX Small and Mid-Cap Conference in Sydney. Auscann is continuing to make steady progress towards releasing its first medicinal cannabis products during the financial year 2019....
on 09/05/2018
2 min read
Prev article
2 min read
